Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone

Benzer Materyaller

• Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
  Yazar:: Pepe, Alessia, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Assessment of the effect of combination therapy with Deferiprone & Desferrioxamine on cardiac complications in major Thalassemia
  Yazar:: F. Rashidi ghader, M.D, ve diğerleri
  Baskı/Yayın Bilgisi: (2007-01-01)
• A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
  Yazar:: Pepe, Alessia, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• A novel mutation in the erythroid transcription factor KLF1 is likely responsible for ameliorating β‐thalassemia major
  Yazar:: Fanis, Pavlos, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Agranulocyosis in Beta Thalassemia Major Patients treated with Oral Iron Chelating Agent (Deferiprone)
  Yazar:: Wali, Yasser, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)